LABU - Direxion Daily S&P Biotech Bull 3X ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
109.91
+4.12 (+3.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close105.79
Open105.00
Bid108.75 x 800
Ask114.21 x 1000
Day's Range104.28 - 110.42
52 Week Range55.10 - 116.54
Volume525,654
Avg. Volume961,171
Net Assets380.74M
NAV94.91
PE Ratio (TTM)N/A
Yield0.02%
YTD Return21.97%
Beta (3y)5.78
Expense Ratio (net)0.95%
Inception Date2015-05-28
Trade prices are not sourced from all markets
  • ETF Trends6 days ago

    Pharma, Biotech Bull ETFs Leading the Charge

    The rising prices of drug treatments, more dependence on immuno-oncology and mergers focused on mid-sized biotech company acquisitions are just a few factors spurning the growth in the biotechnology and pharmaceuticals industry, giving ETFs like  Daily Pharmaceutical & Medical Bull 3X Shares  (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) exceptional returns. PILL seeks investment results equal to 300% of the daily performance of the Dynamic Pharmaceutical Intellidex Index and concentrates its allocations towards securities of the index and other financial instruments that provide daily leveraged exposure to the index. The index itself just matched a previous high and PILL itself is posting year-to-date returns of 6.36% according to performance figures from Yahoo! Finance.

  • ETF Trends26 days ago

    5 Big Direxion ETFs Trending This Week

    Since 1997, Direxion has been providing investment solutions with their innovative ETFs and 20 years later, they have $13.4 billion worth of assets under management. If you haven't already, check out the 5 ETFs below that are trending this week - and are worth keeping an eye on during the second half of 2018. Despite all the talk regarding trade wars with the United States and China, one sector that has been shrugging off the market noise is the biotechnology sector.

  • Biotech Sector Continue to Dazzle Despite Market Distress
    Market Realistlast month

    Biotech Sector Continue to Dazzle Despite Market Distress

    Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes. It doesn’t help that President Trump (seemingly at random) decides periodically that we all pay too much for drugs. For biotech stocks to work on the long side investors’ risk appetite would have to take off or a major approval could drive the stocks up.

  • ETF Trends3 months ago

    Catalysts Abound for Biotech ETFs

    Biotechnology stocks and biotech ETFs tumbled in the back half of March and to start April. For example, the SPDR S&P Biotech ETF (NYSEArca: XBI) came into Monday with a loss of almost 12.6% over the past ...

  • Investopedia5 months ago

    Biotech Stocks Trade Near Major Levels of Support

    With biotech stocks tumbling toward long-term levels of support, we take a closer look at how active traders will trade the bounce.

  • ETF Trends5 months ago

    Healthcare Dip Could be a Buying Opportunity

    The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled last week, but some market observers believe the decline ...

  • 5 Best-Performing Leveraged ETFs of January
    Zacks6 months ago

    5 Best-Performing Leveraged ETFs of January

    Demand for leveraged ETFs is growing as investors seek to register big gains in a short span.

  • The Zacks Analyst Blog Highlights: NAIL, CWEB, LABU, SOXL and EDC
    Zacks7 months ago

    The Zacks Analyst Blog Highlights: NAIL, CWEB, LABU, SOXL and EDC

    The Zacks Analyst Blog Highlights: NAIL, CWEB, LABU, SOXL and EDC

  • Benzinga8 months ago

    Short Interest And Leveraged ETFs

    Short interest is a popular metric on Wall Street because it gives a peek into the amount of negative sentiment a stock has. For their part, leveraged ETFs thrive on the directionality short interest can ...

  • Benzinga8 months ago

    CUREs For The Ordinary December Trade

    December is usually a fine month for stocks, but traders looking to bolster their sector-level returns have some compelling ideas to consider from the world of leveraged exchange traded funds (ETFs). Of ...

  • Benzinga8 months ago

    Latest Tax Reform Bill From Senate GOP Seeks Repeal Of ACA Individual Mandate

    The latest Republican tax reform bill takes yet another stab at the Affordable Care Act with a proposed repeal of individual mandates, party leadership said Tuesday . The mandates had required Americans ...

  • Starting Small Offers Some Protection With Opportunities
    Investor's Business Daily9 months ago

    Starting Small Offers Some Protection With Opportunities

    Fast-moving stocks can turn into your biggest winners but come with a larger risk. A half position in a swing trade can get you a low-cost entry to start.

  • ETF Trends10 months ago

    Biotech, Pharma ETFs Leave Pricing Drama Behind

    Biotechnology and pharmaceutical ETFs have rallied in recent weeks as drug pricing concerns wane and investors look to the opportunity of this market segment. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) ...

  • ETF Trends10 months ago

    Biotech ETF Investing is Hot, Can Get Hotter

    Up more than 42% year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI ) , one of the largest biotechnology ETFs, is one of this year's best-performing non-leveraged ETFs. That does not mean XBI's run ...

  • ETF Trends11 months ago

    Biotech ETFs Remain Bell of the Ball

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotechnology exchange traded fund by assets, and its equal-weight rival, the SPDR S&P Biotech ETF (NYSEArca: XBI) have been soaring in ...

  • Benzinga11 months ago

    A Sign Of Things To Come? Traders Are Betting On More Biotech Mergers

    Even with modest August losses for the S&P 500 and the broader healthcare sector, biotechnology stocks and exchange traded funds (ETFs) are surging. The S&P Biotechnology Select Industry Index is up more ...

  • ETF Trends11 months ago

    Biotech ETF Investing is Starting to Look Good – Here’s Why

    The SPDR S&P Biotech ETF (NYSEArca: XBI) , one of the largest biotechnology exchange traded funds, is getting in on the sector's resurgence. XBI, an equal-weight fund, is up about 7% over the past week, ...

  • Benzingalast year

    4 Things To Know Before Trading A Leveraged ETF

    U.S. ETFs are on pace to have record inflows in 2017. That includes funds dedicated to equities, fixed income, and commodities. And it's easy to see why. With the S&P 500 up 9 percent this year (through ...